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Background The use of adenosine is sometimes considered as a limiting
factor for of fractional flow reserve (FFR) measurements. The present study
sought to quantify the potential of contrast medium (CM) to induce microvascular
dilatation as assessed by the changes in Doppler flow velocity measurements.
Methods In 30 patients, Doppler-derived flow velocity measurements were
obtained in 10 right coronary arteries (RCA) and 20 left coronary arteries (LCA)
free of significant stenosis. Flow velocity was measured at baseline and after
8mL intracoronary (IC) bolus administrations of arterial blood at body tempera-
ture, saline and CM compared to intracoronary boluses of adenosine at room tem-
perature. The hyperemic value was expressed in percent of the maximum flow
velocity reached in a given artery (Q/Qmax, %). To translate the IC adenosine dose
into its effect on FFR, a model based on standard coronary physiology linked the
degree of hyperemia to the relative distal coronary pressure (Pd/Pa). 
Results Doppler flow velocity varied among 8mL IC boluses of arterial
blood, saline and contrast (p<0.001), and all pairwise comparisons were sig-
nificant (p<0.001 for blood and contrast; p=0.041 for saline and blood; and
p=0.013 for saline and contrast). Hyperemic response after injection of 8mL
of CM reached 59±17% of that achieved maximum hyperemia. While Base-
line, arterial blood and saline achieved respectively 38±12%, 45±14% and
51±14% of Q/Qmax. The incidence of transient atrio ventricular blocks was
38% after injection of 200 μg, while it was not observed withcm. According
to our theoretical model, whencm reach 59±17% of that achieved maximum
hyperemia after adenosine in Doppler flow velocity it correspond to a Pd/Pa
ratio of 0.85, where FFR is 0.79 and the resting Pd/Pa is 0.90. 
Conclusion CM reaches approximately 60% of the maximal flow velocity
as compared to Adenosine IC. This corresponds to a difference of only 6%
when “translated” in terms of FFR.
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Introduction Assessment of the functional significance of left anterior
descending coronary artery (LAD) stenosis of intermediate severity (IS) is
challenging. A direct comparison of fractional flow reserve (FFR), instanta-
neous wave-free ratio (IFR), and non-invasive coronary flow reserve (CFR)
has never been performed. Our objective was to test the usefulness of non-
invasive CFR by comparison to invasive FFR and IFR in patients with LAD
stenosis of angiographic IS and stable coronary artery disease. 
Methods 58 stable consecutive patients (mean age, 68±10 years; with
angiographic proximal or mid LAD stenosis of IS (40-70% diameter stenosis
on quantitative coronary angiography), no previous anterior myocardial infarc-
tion, were prospectively studied. They underwent iFR which was calculated as
a trans-lesion pressure ratio during a specific period of baseline diastole, FFR
with intracoronary bolus adenosine (150μg), and CFR using intravenous ade-
nosine (140μg/kg/min over 2min) in the distal part of the LAD, the same day.
CFR was defined as hyperemic peak diastolic LAD flow velocity divided by
baseline flow velocity, and FFR was defined as distal pressure divided by
mean aortic pressure during maximal hyperemia. 
Results The mean values of iFR, FFR, and CFR were 0.88±0.07,
0.81±0.08, and 2.4±0.6 respectively. A significant correlation was found
between CFR and FFR (r=0.72, curvilinear relationship), FFR and IFR
(r=0.63, linear relationship), and between CFR and IFR (r=0.44) (all, p<0.01).
Using a ROC curve analysis, the best cut-off to detect a significant lesion
based on FFR assessment (FFR <0.8, n=16) was iFR ≤0.86 with a sensitivity
(Se) of 75%, specificity (Sp) of 81%, AUC 0.8±0.05; and CFR ≤2 with a Se
of 82%, Sp of 85%, AUC 0.9±0.03, (all, p<0.001). Based on these cut-offs,
discordant results between CFR and FFR were observed in 9 cases (accuracy
84%), between CFR and iFR in 14 cases (accuracy 76%), and between iFR
and FFR in 11 cases (accuracy 81%).
Conclusion In stable patients with LAD stenosis of IS, non-invasive CFR
is a useful tool to detect a significant lesion based on FFR. Furthermore, CFR
is better correlated to FFR than to iFR, and its accuracy seems as good as iFR
in this setting.
The author hereby declares no conflict of interest
0459
Super-Minimalist Immediate Mechanical Intervention (Super-MIMI)
study
Loic Belle* (1), Hend Madiot (2), Hélène Bouvaist (3), Nicolas Delarche (4),
Fréderic Bouisset (5), Pierre-Yves Petiteau (6), Ziad Boueri (7), Mohamed
Abdellaoui (8), Chloé Durier (9), Olivier Dubreuil (10)
(1) Hôpital, Annecy, France – (2) CH Annecy, Annecy, France – (3) CHU
Grenoble, Grenoble, France – (4) CH Pau, Pau, France – (5) CHU Tou-
louse, Toulouse, France – (6) Clinique, Besançon, France – (7) CH Bas-
tia, Bastia, France – (8) Clinique Mutualiste, Grenoble, France – (9) CH
Argenteuil, Argenteuil, France – (10) Clinique St Joseph St Luc, Lyon,
France
*Corresponding author: loic.belle@wanadoo.fr (Loic Belle)
Purpose To evaluate the safety of extended-delay stenting (>7 days
between procedures) in the setting of percutaneous coronary intervention
(PCI) for acute ST-segment elevation myocardial infarction (STEMI).
Methods This ongoing prospective observational study is being conducted
in STEMI patients with a high thrombus burden in the infarct-related artery
(IRA). Patients are enrolled if the operator decides to try to restore the best
TIMI flow with the thinnest tool and defer stent implantation for >7 days
under optimal anticoagulation to reduce thrombus burden. The primary end-
point is the composite of reocclusion of the IRA or sudden death between the
two procedures, and deterioration of the flow (from the final flow achieved
after the first procedure to the initial flow at the second procedure).
Results Between January 2014 and January 2015, 127 patients (of 135 we
will enroll) were enrolled at 14 centres: 110 were men and the mean age±SD was
57.1±13.0 years. 98 patients underwent a primary PCI as the first procedure and
29 patients underwent PCI after fibrinolysis. The final TIMI flow at the first pro-
cedure was 3 in 119 patients, 2 in 7 patients, and 1 in 1 patient and the residual
culprit lesion was 61±24%. Glycoprotein IIb/IIIa inhibitor in 42 patients. The
second procedure was performed between 7 and 26 days after the first. None of
the patients died between the two procedures; 1 patient experienced a reocclusion
of the IRA In all cases, initial TIMI flow in the IRA (at the start of the second
procedure) was the same as or better than the final flow after the first procedure.
A stent was implanted in 80 patients, whereas no significant lesion was docu-
mented in 47 patients. Final results will be presented at the meeting.
Conclusions In PCI for acute STEMI, when the thrombus burden is high,
stenting delayed by 7-26 days with intensive antithrombotic cover appears
safe, with only 1 of 130 patients developing an IRA reocclusion.
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Background Between February 2013 and May 2015, of 2,700 coronary
angioplasty procedures realized in our institution, 200 patients aged 65.6 (23-
94) underwent coronary stenting with Absorb Biovascular Scaffold. 
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Clinical data exercise angina in 30% of the patients, acute coronary syn-
droms in 61%, silent ischaemia in 7% and heart failure in 2%.
Procedural data all stents have been implanted under angiographic con-
trol, only 2 beeing imaged by IVUS, in de novo lesions, through a radial
approach with 6 French guiding catheters, following mandatory predilatation.
67% of patents had single vessel desease, 33% multivessel desease. Left ante-
rior descending artery was the target vessel in 64%, the left circumflex in 19%
and the right coronary artery in 26%. 212 stents have neen sdelivered with
only one failure. 25 patients underwent metallic stenting of other arteries. Side
branch angioplasty had to be performed in 4 cases. 
In hospital follow up No death. One complication withe non Q wave myo-
cardial infraction secondary to side branch occlusion (diagonal branch). One
transient ischaemic attack. 
Out hospital follow up at 22 months (12-27) no stent thrombosis occured.
One patient died of cranial traumatism; two patients (1%) had restenosis at
the margin of the BVS requiring repeated angioplasty. 
Conclusion at nearly two years follow up, our data confirm the safety of
the device and the low rate of reintervention.
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Background Although drug-eluting stents (DES) have been shown to dra-
matically reduce restenosis and improve the rate of event-free survival, the
benefit of DES appears to be limited to restenosis. In this retrospective, single-
center study we aimed to compare the long-term outcomes of DES versus
bare-metal stent (BMS) in large coronary arteries (diameter ≥3.5mm).
Methods A total of 164 consecutive patients (mean age 60 years) required
percutaneous coronary intervention with stents ≥3.5mm in diameter, 84 were
BMS and 80 DES. The primary endpoint was major adverse cardiac events
(MACE) defined as angiographically defined in-stent restenosis (ISR), stent
thrombosis and death from any cause.
Results A mean clinical follow up of 28 months was obtained. The DES
group had higher rates of diabetes (63% vs 37%, p=0.001), previous CAD
(74% vs 25%, p=0.001) and previous PCI (69% vs 31%, p=<0.04). There was
no significant difference between the two groups regarding the rate of hyper-
tension, dyslipidemia, smokers and the mean left ventricular ejection fraction.
There was a higher average stent length in the DES group (18.7 vs 16.3,
p=0.011) as well as a lower average stent diameter (3.54 vs 3.63, p=0.003).
There was a significant difference in MACE between the two groups in favour
of DES (11.3% DES vs 23.8% BMS group, p=0.04) at 28 months. The rate of
in-stent restenosis (ISR) was significantly reduced among patients receiving
DES with ISR rates of 15.8% among patients receiving DES compared to
41.7% among those receiving BMS (p=0.025). There were no significant dif-
ferences in the rate of death or stent thrombosis.
Conclusion In patients requiring stenting of large coronary arteries, there
was reduced MACE in patients treated with DES. This benefit was primarily
driven by decreased in-stent restenosis rate.
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Aims To demonstrate the acute and early outcomes of the Nile PAX dedi-
cated polymer-free paclitaxel-coated stents in the treatment of the coronary
bifurcation lesions. 
Methods and results The Nile PAX device incorporates a cobalt-chromium
alloy with a side aperture in the mid-stent designed to optimize scaffold at the
bifurcation carina and side branch (SB) ostium, while maintaining SB access
during procedure. From January 2012 to December 2014, 36 patients were
included in a retrospective, monocentric study. Lesion criteria were: vessel size
2.5-3.5mm in the parent vessel (PV) and 2.0-3.0mm in the SB, regardless of the
lesion length. Average age was 63,1 years, 22% of patientshad diabetesand 51%
had acute coronary syndrome, while LAD/Dg was involved in 67% of cases.
Percutaneous coronary intervention (PCI) Ad-Hoc was done for 40%of lesions.
SB received additional stent in 8% of procedures and final kissing-balloon infla-
tion was performed in 89% of procedures. There was three non-Q myocardial
infarctions: one during hospitalization, and two up to 6 months.In addition to
these three Major adverse cardiacevents (MACE), two other patients underwent
a target lesion revascularization due to astable angina.
Conclusions Preliminary results of this retro-prospective monocentric
study demonstrated encouraging results with the Nile PAX bifurcation DES in
the treatment of coronary bifurcation lesions, including high device and pro-
cedural success.
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Introduction Instent restenosis (ISR) remains the weak point of coronary
angioplasty despite the advent of drug-eluting stents.The drug eluting balloon
(DEB), which in contact of the artery wall releases an antiproliferative agent,
could be an option to treat ISR or some de novo lesions. 
Methods Between October 2013 and December 2014 in our center, all
patients treated with DEB for RIS or de novo lesions were identified. ISR was
defined as a stenosis of more than 50% or a measuring FFR≤0,8 to a site pre-
viously treated by stent. The lesion was first treated by compliant balloon then
DEB (SeQuent Please® laboratory Braun® B) was inflated for 30 seconds and
then removed. Angiographic control was achieved and, in case of incomplete
result or complication, a stent could be implanted.
Results Among the 48 patients treated with DEB, 23 were for ISR and 25
for de novo lesions. The average age of patients was 75.7 years. 31% of patients
were part of a long-term anticoagulation for atrial fibrillation. The clinical pre-
sentation was mostly a stable angina (62%). In 26% of ISR, there was in DES
restenosis, the average time of ISR was 2 years±3.9. The average diameter of
the DEB used was 2.4mm±0.4 for an average length of 17mm±4.7mm. For five
patients (10%) has a complement of stent implantation (DES in 60% of cases).
The double antiaggregation was continued during 3.8 months. In-hospital, one
death appeared. In the mean follow up of 6.5 months (maximum one year) no
deaths were reported. After revascularization 8% of patients had a clinical
relapse, 12.5% had a positive ischemic test. In 10.4% of cases, a significant rest-
enosis in angioplasty site DEB (TLR) has been highlighted, and requiring a new
revascularization.The average period for TLR was 7.6 months±4.
Conclusion The DEB is a safe option mainly for ISR and for small caliber
arteries, or bifurcation lesions or in the elderly or in long-term anticoagulation.
The clinical course is often satisfactory. 
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Objectives This work reports the concept and the practical feasibility of
Reversed Single String bifurcation stenting technique by demonstrating three
in vitro cases.
